mine

Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session

PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that data from a preclinicalstudy of trodusquemine (MSI-1436) for the treatment of obesity werepresented during the American Diabetes Association (ADA) 67thScientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz,Genaera research scientist and lead author of Abstract #1801-P,present...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that it will present a posteron trodusquemine (MSI-1436), its novel anti-obesity compound,during the American Diabetes Association (ADA) 67th ScientificSessions, June 22 to 25 in Chicago. The abstract, # 1801-P, is titled, "Trodusquemine is a MultiplePathway Inhibitor that Causes Diffe...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex -the novel selective relaxant binding agent (SRBA) being developedby Organon, the human healthcare business unit of Akzo Nobel -demonstrated in a Phase III pivotal trial a 9-12 times fasterreversal of neuromuscular blockade as compared to neostigmine,without evidence of post operative residual curarization (PORC) orre-occurre...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

OSS, the Netherlands, June 11, 2007-Sugammadex - the novelselective relaxant binding agent (SRBA) being developed by Organon,the human healthcare business unit of Akzo Nobel - demonstrated ina Phase III pivotal trial a 9-12 times faster reversal ofneuromuscular blockade as compared to neostigmine, without evidenceof post operative residual curarization (PORC) or re-occurrence ofmuscle relax...

Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP

VIENNA, Austria, June 11, 2007 /PRNewswire/ -- GlaxoSmithKlineplc announced results from an international, pivotal Phase IIIstudy of its investigational non-peptide oral platelet growthfactor, PROMACTA(R) (eltrombopag olamine). Data from this studyshowed that PROMACTA at 50-75mg once daily resulted in astatistically significant increase in platelet counts and alsoreduced bleeding in adul...

Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - JavelinPharmaceuticals, Inc. (AMEX: JAV), a leading developer of novelproducts for pain control, today announced that its Phase 2multi-dose study of Rylomine was published in Pain Medicine, theofficial journal of The American Academy of Pain Medicine. Thearticle, entitled, "Analgesic Efficacy and Safety ofMorphine-Chitosan Nasal Solution in P...

MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007

ATLANTA--(BUSINESS WIRE)--May 22, 2007 - MIV Therapeutics(OTCBB:MIVT) (FWB:MIV), a leading developer of next generationbiocompatible coatings and advanced drug delivery systems forCardiovascular stents and other implantable medical devices, ispleased to announce that results from an animal trial comparing itsproprietary polymer free Hydroxyapatite-coated drug-elutingcardiovascular stent to...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients takingonce-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- Along-term phase III, open-label 12-14 month extension study (303)presented at the British Society of Gastroenterology (BSG) meetingin Glasgow, Scotland in March 2007 showed Shire plc'sLialda(mesalamine) is w...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ --Catalyst Pharmaceutical Partners, Inc. announced today positiveinitial, top-line results from a bioequivalence study demonstratingthat CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable andbioequivalent to Sabril Tablets, the version of vigabatrin marketedin Europe by Sanofi Aventis. These data potentially provide a basisfor...

Early Results of the CellCept Spare the Nephron Study Examine Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results froma multicenter trial investigating a novel kidney-sparing treatmentprotocol using CellCept(R) (mycophenolate mofetil) were presentedat the American Transplant Congress. This and other Spare theNephron (STN) trials in kidney and liver transplant recipientsexamine ways to prevent rejection without damaging kidneys. As tra...

Karmanos Physician-Scientists Examine Racial Disparities in Patients with Gynecologic Cancer

DETROIT, April 16, 2007 /PRNewswire/ -- Karmanos CancerInstitute physician-scientists today reported on two researchstudies investigating racial disparities in patients withgynecologic cancer at the American Association of Cancer Researchannual meeting in Los Angeles, CA. Caucasian patients with endometrial or ovarian cancer, onaverage, live longer than their African American count...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InterleukinGenetics, Inc. (AMEX:ILI) and collaborators at the University ofCalifornia San Diego today reported at the American College ofCardiology annual meeting that associations between coronary arterydisease (CAD) and both oxidized phospholipids (OxPL) and Lp(a)levels appear to be dependent on pro-inflammatory variants of theinterleukin-1...